Hsin‐hsiung Tai

Hsin‐hsiung Tai's AcademicInfluence.com Rankings

Hsin‐hsiung Tai

Biology

#13022

World Rank

#16539

Historical Rank

Biochemistry

#2248

World Rank

#2395

Historical Rank

biology Degrees

Download Badge

Biology

Hsin‐hsiung Tai's Degrees

PhD Biochemistry University of California, Berkeley
Bachelors Chemistry National Taiwan University

Why Is Hsin‐hsiung Tai Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hsin‐hsiung Tai's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function. (1974) (508)
Prostaglandin catabolizing enzymes. (2002) (341)
15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Colorectal Cancer* (2005) (312)
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. (2004) (252)
Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration (2015) (206)
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. (2006) (200)
Oxidoreductases in Lipoxin A4 Metabolic Inactivation (2000) (169)
Most efficient cocaine hydrolase designed by virtual screening of transition states. (2008) (165)
Computational redesign of human butyrylcholinesterase for anticocaine medication. (2005) (161)
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. (2004) (157)
Immunohistochemical localization, messenger ribonucleic acid abundance, and activity of 15-hydroxyprostaglandin dehydrogenase in placenta and fetal membranes during term and preterm labor. (1994) (145)
Metabolism of Prostaglandin Glycerol Esters and Prostaglandin Ethanolamides in Vitro and in Vivo * (2001) (138)
15-Hydroxyprostaglandin dehydrogenase. (1995) (133)
Development of cyclooxygenase and lipoxygenase metabolites of arachidonic acid after transient cerebral ischemia. (1986) (133)
NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. (2006) (124)
Stimulation of de novo synthesis of prostaglandin G/H synthase in human endothelial cells by phorbol ester. (1988) (114)
Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. (1998) (112)
Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. (2015) (112)
Leukotriene B4 Release and Polymorphonuclear Cell Infiltration in Spinal Cord Injury (1990) (110)
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors (2009) (104)
Thromboxanes: synthase and receptors. (1998) (103)
Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. (1990) (96)
On the inhibitory potency of imidazole and its derivatives on thromboxane synthetase. (1978) (95)
Formation of Prostaglandins E2 and D2 via the Isoprostane Pathway (2003) (92)
Pioglitazone and Rosiglitazone Decrease Prostaglandin E2 in Non–Small-Cell Lung Cancer Cells by Up-Regulating 15-Hydroxyprostaglandin Dehydrogenase (2007) (90)
Site-directed mutagenesis of the conserved tyrosine 151 of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase yields a catalytically inactive enzyme. (1991) (90)
Design, Preparation, and Characterization of High-Activity Mutants of Human Butyrylcholinesterase Specific for Detoxification of Cocaine (2011) (84)
Biosynthesis of prostaglandins in rabbit kidney medulla. Properties of prostaglandin synthase. (1976) (82)
Squalene epoxidase of rat liver. (1972) (81)
Immunocytochemical distribution and localization of 15-hydroxyprostaglandin dehydrogenase in human fetal membranes, decidua, and placenta. (1990) (78)
15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric Cancer (2009) (78)
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. (2007) (76)
Release of arachidonate from diglyceride in human platelets requires the sequential action of a diglyceride lipase and a monoglyceride lipase. (1981) (76)
Urinary Prostaglandin F2α Is Generated from the Isoprostane Pathway and Not the Cyclooxygenase in Humans* (2007) (75)
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. (2006) (74)
Phorbol ester, 1,2-diacylglycerol, and collagen induce inhibition of arachidonic acid incorporation into phospholipids in human platelets. (1989) (71)
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. (2007) (64)
Prostaglandin catabolic enzymes as tumor suppressors (2011) (64)
Synergistic stimulation of thromboxane biosynthesis by calcium ionophore and phorbol ester or thrombin in human platelets. (1985) (64)
Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. (2006) (60)
Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. (2005) (59)
Gossypol, a potent inhibitor of arachidonate 5- and 12-lipoxygenases. (1985) (59)
Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. (2006) (59)
Development of radioimmunoassay for thromboxane B2. (1978) (59)
Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. (2009) (57)
Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells. (1996) (55)
Enzymatic synthesis of (15s)-[15-3h]prostaglandins and their use in the development of a simple and sensitive assay for 15-hydroxyprostaglandin dehydrogenase. (1976) (55)
Activation of thromboxane A(2) receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. (2009) (54)
Activation of Thromboxane A2 Receptor (TP) Increases the Expression of Monocyte Chemoattractant Protein -1 (MCP-1)/Chemokine (C-C motif) Ligand 2 (CCL2) and Recruits Macrophages to Promote Invasion of Lung Cancer Cells (2013) (52)
Differential changes in 15-hydroxyprostaglandin dehydrogenase and prostaglandin H synthase (types I and II) in human pregnant myometrium. (2002) (51)
Arachidonic Acid and Its Metabolites in Cerebral Ischemia a (1989) (51)
Localization of 15-hydroxy prostaglandin dehydrogenase in human fetal membranes, decidua, and placenta during pregnancy. (1992) (50)
Abnormal platelet response to thromboxane A2. (1981) (50)
Characterization of recombinant human CXCR4 in insect cells: role of extracellular domains and N-glycosylation in ligand binding. (1999) (50)
Stimulations of arachidonate release and inositol-1,4,5-triphosphate formation are mediated by distinct G-proteins in human platelets. (1987) (49)
Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. (2000) (49)
Novel human mPGES-1 inhibitors identified through structure-based virtual screening. (2011) (49)
NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase Regulates Levels of Bioactive Lipids in Non–Small Cell Lung Cancer (2008) (49)
Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. (1994) (49)
Preterm birth without progesterone withdrawal in 15-hydroxyprostaglandin dehydrogenase hypomorphic mice. (2008) (47)
Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors. (2011) (47)
Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. (2002) (46)
Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. (2010) (45)
Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. (2002) (45)
Plasma secretin and gastrin responses to a meat meal and duodenal acidification in dogs. (1976) (44)
Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. (2004) (44)
Polyamine and prostaglandin markers in focal cerebral ischemia. (1985) (44)
Rapid extraction of secretin from plasma by XAD-2 resin and its application in the radioimmunoassay of secretin. (1978) (43)
Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis. (2010) (43)
Immunoaffinity purification and characterization of thromboxane synthase from porcine lung. (1986) (41)
Simultaneous radioimmunoassay of Secretin and gastrin. (1976) (41)
Prostaglandin 9-ketoreductase/type II 15-hydroxyprostaglandin dehydrogenase is not a prostaglandin specific enzyme. (1981) (39)
Plasma secretin concentrations in fasting and postprandial state in man (1978) (39)
Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors. (2010) (39)
Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. (2008) (38)
Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. (2002) (38)
Diglyceride/monoglyceride lipases pathway is not essential for arachidonate release in thrombin-activated human platelets. (1983) (38)
Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. (1998) (38)
The Escherichia coli-derived Fab fragment of the IgM/kappa antibody IN-1 recognizes and neutralizes myelin-associated inhibitors of neurite growth. (1996) (37)
Expression and site-directed mutagenesis of mouse prostaglandin E2 receptor EP3 subtype in insect cells. (1995) (36)
Preparation and in vivo characterization of a cocaine hydrolase engineered from human butyrylcholinesterase for metabolizing cocaine. (2013) (35)
Interleukin-1 beta and dexamethasone regulate gene expression of prostaglandin H synthase-2 via the NF-kB pathway in human amnion derived WISH cells. (1998) (35)
Expression and functional characterization of mutant human CXCR4 in insect cells: role of cysteinyl and negatively charged residues in ligand binding. (2000) (35)
Stimulation of synthesis de novo of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase in human promyelocytic leukaemia (HL-60) cells by phorbol ester. (1991) (35)
Preparation of 125I-labeled secretin of high specific radioactivity. (1975) (34)
Radioimmunoassay of motilin. Validation and studies on the relationship between plasma motilin and interdigestive myoelectric activity of the duodenum of dog. (1978) (34)
Histone deacetylase inhibitors and transforming growth factor-β induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells (2006) (34)
Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site-directed mutagenesis. (2006) (33)
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase from porcine kidney. I. Purification and partial characterization. (1980) (33)
Characterization of the genomic structure and promoter of the mouse NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene. (1997) (33)
Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells. (2004) (31)
Thromboxane A2 receptor‐mediated release of matrix metalloproteinase‐1 (MMP‐1) induces expression of monocyte chemoattractant protein‐1 (MCP‐1) by activation of protease‐activated receptor 2 (PAR2) in A549 human lung adenocarcinoma cells (2014) (31)
Prostaglandin E2 alterations during sepsis are partially mediated by endotoxin-induced inhibition of prostaglandin 15-hydroxydehydrogenase. (1997) (30)
Prostaglandin 9-ketoreductase and type II 15-hydroxyprostaglandin dehydrogenase from swine kidney are alternate activities of a single enzyme protein. (1981) (30)
Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs). (2011) (29)
Role of glutamine 148 of human 15-hydroxyprostaglandin dehydrogenase in catalytic oxidation of prostaglandin E2. (2006) (29)
Calcium stimulation of a novel 12-lipoxygenase from rat basophilic leukemia (RBL-1) cells. (1984) (29)
Monoclonal antibodies to thromboxane synthase from porcine lung. Production and application to development of a tandem immunoradiometric assay. (1986) (29)
Hypoxia stimulates prostacyclin generation by dog lung in vitro. (1982) (28)
Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells. (2007) (28)
Regulation of synthesis and activity of NAD(+)-dependent 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) by dexamethasone and phorbol ester in human erythroleukemia (HEL) cells. (1991) (27)
Phosphorylation and desensitization of the human thromboxane receptor-alpha by G protein-coupled receptor kinases. (2001) (26)
Development of radioimmunoassay for motilin. (1978) (26)
12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT) is an excellent substrate for NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. (1985) (25)
Induction of fatty acid cyclooxygenase in rat aortic smooth muscle cells by estradiol. (1983) (25)
The role of N-glycosylation of human thromboxane A2 receptor in ligand binding. (1998) (25)
Threonine 188 is critical for interaction with NAD+ in human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. (1999) (24)
Differential production of prostaglandin E(2) in male and female mice subjected to thermal injury contributes to the gender difference in immune function: possible role for 15-hydroxyprostaglandin dehydrogenase. (2000) (24)
Elevated thromboxane B2 levels in periodontal disease. (1981) (24)
Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA (1993) (24)
Radioimmunoassay of vasoactive intestinal polypeptide. (1979) (24)
Critical residues for the coenzyme specificity of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. (2003) (23)
15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells. (2005) (23)
Hypoxia provokes leukotriene-dependent neutrophil sequestration in perfused rabbit hearts. (1987) (23)
Expression of two different forms of cDNA for thromboxane synthase in insect cells and site-directed mutagenesis of a critical cysteine residue. (1993) (23)
Purification of thromboxane synthetase and evidence of two distinct mechanisms for the formation of 12-L-hydroxy-5,8,10-heptadecatrienoic acid by porcine lung microsomes. (1981) (23)
9-Hydroxyprostaglandin dehydrogenase from rat kidney. Purification to homogeneity and partial characterization. (1980) (23)
Burn injury with infection alters prostaglandin E2 synthesis and metabolism. (1998) (23)
Transformation of arachidonate into 6-oxoprostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 by sheep lung microsomal fraction. (1978) (23)
15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. (2009) (22)
Phenylalanine 138 in the second intracellular loop of human thromboxane receptor is critical for receptor-G-protein coupling. (1999) (22)
Selective inhibition of leukotriene B4 biosynthesis in rat pulmonary alveolar macrophages by dietary selenium deficiency. (1985) (22)
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345 (1990) (22)
Site-directed mutagenesis of the conserved serine 138 of human placental NAD+-dependent 15-hydroxyprostaglandin dehydrogenase to an alanine results in an inactive enzyme. (1996) (22)
Cloning and expression of the cDNA for mouse NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. (1996) (22)
Serine 331 is the major site of receptor phosphorylation induced by agents that activate protein kinase G in HEK 293 cells overexpressing thromboxane receptor alpha. (2001) (22)
Mechanism of prostaglandin biosynthesis in rabbit kidney medulla. A rate-limiting step and the differential stimulatory actions of L-adrenaline and glutathione. (1976) (21)
Stimulation of prostaglandin E2 synthesis by interleukin-1beta is amplified by interferons but inhibited by interleukin-4 in human amnion-derived WISH cells. (1996) (21)
Monoglyceride and diglyceride lipases from human platelet microsomes. (1988) (20)
Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes. (2009) (20)
Stimulation of 12-lipoxygenase activity in rat platelets by 17β-estradiol (1982) (20)
Photoaffinity labeling of human placental NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase with [alpha-32P]2N3NAD+. Identification of a peptide in the adenine ring binding domain. (1993) (19)
Delayed elevation of platelet activating factor in ischemic hippocampus (1995) (19)
Stimulation of cyclic nucleotide phosphodiesterase by products of phosphatidylinositol metabolism catalyzed by phospholipase A2. (1982) (19)
A radioimmunoassay for 6-ketoprostaglandin E1. (1982) (19)
15‐hydroxyprostaglandin dehydrogenase suppresses K‐RasV12‐dependent tumor formation in Nu/Nu mice (2008) (19)
Radioimmunological assay of prostacyclin synthetase activity. (1980) (19)
Selective inhibition of thromboxane synthetase by pyridine and its derivatives. (1980) (19)
Monoclonal antibodies that inhibit the enzyme activity of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. (1990) (18)
Radioimmunoassay of motilin (1978) (18)
A simple and sensitive assay for 9-hydroxyprostaglandin dehydrogenase. (1977) (18)
Increased expression of matrix metalloproteinases mediates thromboxane A2-induced invasion in lung cancer cells. (2012) (18)
Glycogen Synthase Kinase-3 Phosphorylation, T-Cell Factor Signaling Activation, and Cell Morphology Change following Stimulation of Thromboxane Receptor α (2006) (17)
Regulation of prostaglandin metabolism: activation of 15-hydroxyprostaglandin dehydrogenase by chlorpromazine and imipramine related drugs. (1976) (17)
Oxidoreductases in Lipoxin A4 Metabolic Inactivation. A Novel Role for 15-oxoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in Inflammation (2000) (17)
Restoration of leukotriene B(4)-12-hydroxydehydrogenase/15- oxo-prostaglandin 13-reductase (LTBDH/PGR) expression inhibits lung cancer growth in vitro and in vivo. (2010) (17)
Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid (2009) (16)
High-sensitivity radioimmunoassay screening method for fentanyl. (1986) (16)
Intramolecular ADP-ribose transfer reactions and calcium signalling. Potential role of 2'-phospho-cyclic ADP-ribose in oxidative stress. (1997) (15)
Cysteine 182 is essential for enzymatic activity of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. (1996) (15)
A facile synthesis of an aldehydic analog of platelet activating factor and its use in the production of specific antibodies. (1990) (15)
Cloning and expression of the cDNA for rat NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. (1997) (15)
The porcine thromboxane synthase-encoding cDNA: sequence, mRNA expression and enzyme production in Sf9 insect cells. (1994) (15)
Metabolism of prostaglandins in spontaneously hypertensive rats: NAD"-dependent 15-hydroxyprostaglandin dehydrogenase activity is decreased in kidney and increased in lung. (1979) (14)
Dexamethasone inhibits the induction of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase by phorbol ester in human promonocytic U937 cells. (2000) (14)
Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells. (2010) (14)
Observations on plasma secretion levels by radioimmunoassay in response to duodenal acidification and to a meat meal in humans (1976) (14)
Impairment of secretin release in celiac sprue (1978) (14)
Characterization of two enzyme proteins catalyzing NADP+/NADPH-dependent oxidoreduction of prostaglandins at C-9 and C-15 from swine kidney. (1982) (14)
Non-isotopic immunoassay drug tests in racing horses: a review of their application to pre- and post-race testing, drug quantitation, and human drug testing. (1988) (13)
Group B Streptococcus Promotes Oxygen Radical-Dependent Thromboxane Accumulation in Young Piglets (1990) (13)
Prostaglandin E2 receptor EP3alpha subtype: the role of N-glycosylation in ligand binding as revealed by site-directed mutagenesis. (1998) (13)
Morphine and etorphine: XIV. Detection by ELISA in equine urine. (1991) (13)
Cigarette smoking stimulates lipoxygenase but not cyclooxygenase pathway in platelets. (1983) (13)
Inactivation of pulmonary NAD+-dependent 15-hydroxyprostaglandin dehydrogenase by acrolein. (1985) (12)
An improved method of radioiodination with chloramine T. (1994) (12)
Inhibition of thromboxane synthesis and platelet aggregation by pyridine and its derivatives. (1980) (12)
Purification and characterization of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase from porcine kidney. (1990) (12)
Selective inhibition of 5-lipoxygenase pathway in rat pulmonary alveolar macrophages by cigarette smoking. (1987) (12)
Studies on the thromboxane synthesizing system in human platelet microsomes. (1978) (12)
Monoclonal anti-idiotypic antibodies to platelet activating factor (PAF) and their interaction with PAF receptors. (1991) (11)
Synthesis of [5,6-3H]arachidonic acid and its use in development of a sensitive assay for prostacyclin synthetase. (1980) (11)
Key NAD+-binding residues in human 15-hydroxyprostaglandin dehydrogenase. (2005) (11)
Cyclic AMP response element mediates dexamethasone induced suppression of prostaglandin H synthase-2 gene expression in human amnion derived WISH cells. (1999) (11)
NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase: immunochemical characterization of the lung enzyme from pregnant rabbits. (1990) (11)
C-Terminal region of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase is involved in the interaction with prostaglandin substrates. (2001) (11)
Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells. (2007) (11)
Changes in prostacyclin and thromboxane biosynthesis and their catabolic enzyme activity in kidneys of aging rats. (1984) (10)
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. (2006) (10)
Threonine 11 of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase may interact with NAD(+) during catalysis. (2002) (10)
Agents that elevate cyclic AMP induce receptor phosphorylation primarily at serine 331 in HEK 293 cells overexpressing human thromboxane receptor alpha. (2002) (9)
Identification of metabolites of azaperone in horse urine. (1996) (9)
Increase in thromboxane B2 and decrease in prostaglandin E2 and 6-keto-prostaglandin F1 alpha release into rat bronchoalveolar fluid as a consequence of cigarette smoking. (1987) (9)
NAD+-dependent 15-hgydroxyprostaglandin dehydrogenase from porcine kidney. II. Kinetic studies. (1980) (9)
Changes in arachidonate metabolism in aortas and platelets in aging rats. (1983) (9)
14-3-3ζ interacts with human thromboxane receptors and is involved in the agonist-induced activation of the extracellular-signal-regulated kinase (2006) (9)
Pulmonary NAD+-linked 15-hydroxyprostaglandin dehydrogenase activity is decreased by cigarette smoking. (1984) (9)
Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation. (2005) (9)
Purification of NADP+/NADPH-dependent 15-hydroxyprostaglandin dehydrogenase and prostaglandin 9-ketoreductase from porcine kidney. (1982) (9)
Alteration of platelet activating factor (PAF) metabolism in rat pulmonary alveolar macrophages and plasma by cigarette smoking. (1992) (9)
Induction of a decrease in renal NAD+-dependent 15-hydroxyprostaglandin dehydrogenase activity by estradiol in rats. (1985) (9)
Does protein kinase C activation mediate thrombin-induced arachidonate release in human platelets? (1988) (8)
Effects of testosterone on the metabolism of arachidonic acid by aortas and platelets in rats. (1982) (8)
Pharmacologic effects and detection methods of methylated analogs of fentanyl in horses. (1989) (8)
Alterations of arachidonate metabolism in cardiovascular system by cigarette smoking. (1990) (8)
Cigarette smoke-induced alterations in the release of arachidonate metabolites by pulmonary alveolar macrophage from selenium-fed and selenium-deficient rats. (1986) (7)
Structure and function of prostanoid receptors as revealed by site-directed mutagenesis. (1997) (7)
Serine 331 is major site of phosphorylation and desensitization induced by protein kinase C in thromboxane receptor alpha. (2002) (7)
Enzyme immunoassay of two nicergoline metabolites, 10 alpha-methoxy-9, 10-dihydrolysergol (MDL) and 1-methyl-10 alpha-methoxy-9, 10-dihydrolysergol (MMDL). (1996) (7)
Phorbol ester induces inhibition of arachidonate incorporation into phospholipids in human neutrophils. (1990) (7)
Resolution into two different forms and study of the properties of phosphatidylinositol-specific phospholipase C from human platelet cytosol. (1982) (7)
Age-dependent mechanism in guinea pig bronchoconstriction induced by exsanguination. (1995) (7)
Immunoassay detection of drugs in racing horses. XI. ELISA and RIA detection of fentanyl, alfentanil, sufentanil and carfentanil in equine blood and urine. (1989) (6)
Streptococcus pneumoniae-induced alterations in levels of circulating thromboxane and prostacyclin: dissociation from granulocytopenia, thrombocytopenia, and pulmonary leukostasis. (1986) (6)
A radioimmunoassay for human glucose phosphate isomerase: measurement of immunoreactive enzyme from genetic variants. (1980) (6)
Roles of the vagus in endogenous release of secretin and exocrine pancreatic secretion in dog. (1978) (6)
Ser-268 Plays an Important Role in Ligand Binding of Prostaglandin E2Receptor EP3αSubtype (1996) (5)
Immunoassay detection of drugs in racing horses. IV. Detection of fentanyl and its congeners in equine blood and urine by a one step ELISA assay. (1988) (5)
Radioimmunoassay for etorphine in horses with a 125I analog of etorphine. (1988) (5)
14-3-3zeta interacts with human thromboxane receptors and is involved in the agonist-induced activation of the extracellular-signal-regulated kinase. (2006) (5)
Purification and assay of 9-hydroxyprostaglandin dehydrogenase from rat kidney. (1982) (5)
Bacterial expression of functional membrane-bound thromboxane synthase having intact sequence and truncated N-terminal hydrophobic segment. (1995) (5)
Structure and function of human NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase. (2002) (5)
Increase in enzyme activities of prostaglandin biosynthesis and catabolism by acute ureteral ligation in rat kidney. (1985) (5)
Monoclonal anti-idiotypic antibody to a potent thromboxane A2 receptor antagonist and its interaction with thromboxane A2 receptor. (1993) (5)
Purification and characterization of an NAD(+)-dependent dehydrogenase that catalyzes the oxidation of thromboxane B2 at C-11 from porcine liver. Development and application of 11-dehydro-thromboxane B2 radioimmunoassay to enzyme assay. (1990) (5)
15-Hydroxyprostaglandin Dehydrogenase Protein Expression in Human Fetal Membranes With and Without Subclinical Inflammation (2007) (5)
Ser-268 plays an important role in ligand binding of prostaglandin E2 receptor EP3alpha subtype. (1996) (4)
Oxygen radicals in the nonvagal component of noncholinergic airway constriction. (1996) (4)
Polycyclic aromatic hydrocarbons affect the calcium ionophore induced activation of rabbit platelet (1990) (4)
A radioimmunoassay for prostaglandin endoperoxide synthetase. (1984) (4)
Expression of the cDNA for NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase as a catalytically active enzyme in Escherichia coli. (1992) (4)
Regulatory mechanism of arachidonic acid metabolism in rat basophilic leukemia (RBL)-2H3 cells. (1987) (4)
Immunoassay detection of drugs in racing horses: detection of ethacrynic acid and bumetanide in equine urine by ELISA. (1994) (4)
Partial characterization of a low-molecular-weight, macrophage-derived inhibitor of DNA synthesis: a possible immunoregulatory molecule. (1989) (3)
Expression and Stimulates Cell Proliferation in Human Lung Cancer Cells (2009) (3)
Purification and characterization of phosphatidylinositol kinase from porcine liver microsomes. (1988) (3)
INHIBITION OF 15‐HYDROXYPROSTAGLANDIN DEHYDROGENASE ACTIVITY BY NEAR‐ULTRAVIOLET LIGHT AND TRYPTOPHAN PHOTOPRODUCTS * (1979) (3)
Immunoassay detection of drugs in racing horses. VII. Detection of acepromazine in equine urine and blood by ELISA and PCFIA. (1988) (3)
Site-directed mutagenesis studies of the NADPH-binding domain of rat steroid 5alpha-reductase (isozyme-1) I: analysis of aromatic and hydroxylated amino acid residues. (1999) (3)
Formation of Prostaglandin E 2 and Prostaglandin D 2 Via the Isoprostane Pathway: A Mechanism for the Generation of Bioactive Prostaglandins Independent of the Cyclooxygenase (2003) (3)
Stimulation of 12-lipoxygenase activity in rat platelets by 17 beta-estradiol. (1982) (3)
Expression of rat steroid 5α-reductase (isozyme-1) in Spodoptera Frugiperda, SF21, insect cells: Expression of rat steroid 5α-reductase (1997) (3)
Immunoassay detection of drugs in racing horses. VI. Detection of furosemide (Lasix) in equine blood by a one step ELISA and PCFIA. (1988) (3)
Rubber additives inhibit the calcium ionophore and thrombin induced activation of rabbit platelets (1991) (2)
Kinetic evidence of a distinct regulatory site on 15-hydroxyprostaglandin dehydrogenase. (1976) (2)
Quantitation of 13-hydroxyoctadecadienoic acid (13-HODE) by radioimmunoassay. (1990) (2)
Regulation of arachidonate release by G-proteins and protein kinase C in human platelets. (1989) (2)
Assay of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase using (15S)-[15-3H]PGE2. (1982) (2)
Effects of estradiol on arachidonate metabolism in the rat vascular system. (1985) (2)
Molecular, catalytic, and immunological characterization of NAD+-linked 15-hydroxyprostaglandin dehydrogenase. (1985) (2)
A sensitive enzyme immunoassay for cyclosporin A using antibodies generated against a novel hapten. (1995) (2)
Cloning, Expression and Site-Directed Mutagenesis of the cDNA for Human Placental NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase (1991) (2)
Expression of rat steroid 5 alpha-reductase (isozyme-1) in Spodoptera frugiperda, SF21, insect cells: expression of rat steroid 5 alpha-reductase. (1997) (2)
[Isolation and purification of a NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase from human placenta]. (1993) (1)
Improved sensitivity of enzyme immunoassay for cocaine and benzoylecgonine using heterologous hapten-enzyme conjugates (1994) (1)
Butyric acid enhances cyclooxygenase activity in rat basophilic leukemia 2H3 cells. (1988) (1)
A sensitive and specific radioimmunoassay for platelet-activating factor (1992) (1)
Intracellular translocation of rap 1-B G-protein induced by prostaglandin E1 is blocked by phorbol ester in human platelets. (1994) (1)
AN 125I‐LABELED N6‐SUBSTITUTED AZIDO ANALOG OF NAD+ FOR THE PHOTOAFFINITY LABELING OF NAD+‐LINKED ENZYMES (1994) (1)
Early pregnancy loss in 15-hydroxyprostaglandin dehydrogenase knockout (15-HPGD−/−) mice due to requirement for embryo 15-HPGD activity (2019) (1)
[Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. (1983) (1)
Immunological studies on thromboxane synthase. (1987) (1)
Immunoassay detection of drugs in racing horses. IX. Detection of detomidine in equine blood and urine by radioimmunoassay. (1989) (1)
Enzyme immunoassay of thromboxane B2 using immobilized hapten and enzyme amplification. (1989) (1)
(15-PGDH) BEHAVES AS A TUMOR SUPPRESSOR IN LUNG CANCER 1 (2004) (1)
[Rat basophilic leukemia-1 cell possesses 12-lipoxygenase and 5-lipoxygenase activities which are specifically inhibited by gossypol acetic acid]. (1984) (1)
Thiamine transporter gene expression and exogenous thiamine modulate expression of genes in breast and lung cancers (2004) (1)
Assay of thromboxane A synthase inhibitors. (1982) (1)
[17] Assay of thromboxane a synthase inhibitors☆ (1982) (1)
Improved synthesis of (5Z)-7-(3-endo-[(benzenesulfonamido)-bicyclo[2.2.1]heptyl]hept-5-enoic acid (S-145) derivatives and their iodine-125-labeled radioligands for the study of thromboxane A2 receptor. (1993) (1)
Synergism between chemotactic peptide and platelet-activating factor in stimulating thromboxane B2 and leukotriene B4 biosynthesis in human neutrophils. (1989) (1)
Characterization of (5Z)-7-[3-endo-[(4-iodophenylsulfonyl) amino] -bicyclo[2.2.1]hep-2-exo-yl]heptenoic acid (IS-145) as an antagonist for the study of thromboxane A2 receptor. (1993) (0)
Purification and characterization of a novel GTP-binding protein from human platelet cytosol (1987) (0)
STRUCTURE AND FUNCTION OF PROSTANOID (1997) (0)
Photoaffinity labeling of NAD(+)-linked enzymes. (1997) (0)
Expression and site-directed mutagenesis of mouse prostaglandin E2 receptor EP3 subtype in insect cells (2005) (0)
Possible mechanisms of cigarette smoke induced decrease in NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-OH-PGDH) activity in lung (1984) (0)
Composition of, Method of Producing and Method of Using a Stabilized Formulation for Assaying Peroxide Activity (2018) (0)
Thromboxanes: Synthase and Receptors (1998) (0)
Mecham of Prostaglandin Biosynthesis in Rabbit Kidney Medulla (2005) (0)
Calcium ionophore potentiates chemotactic peptide and platelet activating factor in stimulating thromboxane B2 and leukotriene B4 biosynthesis in human neutrophils. (1990) (0)
TZDs suppress PGE2 via COX-2 dependent and independent pathways in NSCLC. (2006) (0)
[Effect of cigarette smoking on platelet-thromboxane A2 and arterial-prostacyclin synthesis in rats]. (1988) (0)
Abnormal platelet response to thromboxane A2 (2018) (0)
Assay of prostacyclin synthase using [5,6-3H]PGH2. (1982) (0)
Structure and function of prostaglandin metabolic enzymes (1999) (0)
Radioimmunoassay of 11-keto-TXB/sub 2/ and its use in the assay and purification of 11-hydroxythromboxane B/sub 2/ dehydrogenase from porcine liver (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hsin‐hsiung Tai?

Hsin‐hsiung Tai is affiliated with the following schools:

University of Kentucky